In women diagnosed with uterine papillary serous carcinoma (UPSC) and with a history of breast cancer (UPSCBR+), or with UPSC and without a history of breast cancer (UPSCBR-), a recent study found no difference in progression-free survival (PFS) and overall survival (OS). Furthermore, prior tamoxifen exposure was not associated with survival outcomes in patients with UPSC and breast cancer. Researchers also found:
- Among 323 patients with UPSC, 46 (14%) were UPSCBR+; 15 (33%) of these had a history of tamoxifen use.
- UPSCBR+ women demonstrated no significant differences in PFS or OS compared to UPSCBR- women, even after controlling for age.
- There was no difference in PFS or OS with or without tamoxifen exposure within the UPSCBR+ cohort.
Pierce SR, Stine JE, Gehrig PA, et al. Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma. [Published online ahead of print January 3, 2017]. Gynecol Oncol. doi:10.1016/j.ygyno.2016.12.024.